Matches in SemOpenAlex for { <https://semopenalex.org/work/W1893060198> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W1893060198 endingPage "189" @default.
- W1893060198 startingPage "186" @default.
- W1893060198 abstract "Treatment with the tumor necrosis factor-alpha antibody adalimumab for 12-16 weeks produces a satisfactory response [i.e., 75% reduction in psoriasis area and severity index (PASI)] in a majority (70-80%) of patients with psoriasis. We asked whether 311 nm ultraviolet B (UVB) can improve therapeutic response of psoriatic lesions to adalimumab.Four patients (age range, 49-67 years) with moderate to severe plaque-type psoriasis were treated with standard dosage of adalimumab. During adalimumab therapy, a randomly selected body half (left or right, excluding the head) was irradiated with 311 nm UVB three times weekly for 6 weeks. Treatment response was monitored weekly in terms of half-body PASI.311 nm UVB significantly accelerated the therapeutic response during adalimumab treatment. At the start of 311 nm UVB therapy, the mean PASI was 14.8. After 6 weeks of 311 nm UVB therapy, the mean PASI was 2.0 on UV-irradiated body halves and 6.9 on non-irradiated body halves (difference, 4.9; 95% confidence interval, 0.4-9.4; P=0.041; 2-tailed paired t-test). This corresponded to an overall mean PASI reduction from baseline (i.e., adalimumab start) of 86% on UV-irradiated body halves vs. 53% on non-irradiated body halves.311 nm UVB may accelerate and improve the clearance of psoriatic lesions in adalimumab-treated patients." @default.
- W1893060198 created "2016-06-24" @default.
- W1893060198 creator A5012583326 @default.
- W1893060198 creator A5043882524 @default.
- W1893060198 creator A5048094864 @default.
- W1893060198 creator A5064351361 @default.
- W1893060198 creator A5064574530 @default.
- W1893060198 creator A5084293838 @default.
- W1893060198 date "2011-07-05" @default.
- W1893060198 modified "2023-10-13" @default.
- W1893060198 title "311 nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients" @default.
- W1893060198 cites W1989308717 @default.
- W1893060198 cites W2000060610 @default.
- W1893060198 cites W2011677886 @default.
- W1893060198 cites W2069350424 @default.
- W1893060198 cites W2101126063 @default.
- W1893060198 cites W2109745257 @default.
- W1893060198 cites W2132699054 @default.
- W1893060198 cites W2163232748 @default.
- W1893060198 doi "https://doi.org/10.1111/j.1600-0781.2011.00594.x" @default.
- W1893060198 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21729166" @default.
- W1893060198 hasPublicationYear "2011" @default.
- W1893060198 type Work @default.
- W1893060198 sameAs 1893060198 @default.
- W1893060198 citedByCount "42" @default.
- W1893060198 countsByYear W18930601982012 @default.
- W1893060198 countsByYear W18930601982013 @default.
- W1893060198 countsByYear W18930601982014 @default.
- W1893060198 countsByYear W18930601982015 @default.
- W1893060198 countsByYear W18930601982016 @default.
- W1893060198 countsByYear W18930601982017 @default.
- W1893060198 countsByYear W18930601982018 @default.
- W1893060198 countsByYear W18930601982019 @default.
- W1893060198 countsByYear W18930601982020 @default.
- W1893060198 countsByYear W18930601982021 @default.
- W1893060198 countsByYear W18930601982022 @default.
- W1893060198 crossrefType "journal-article" @default.
- W1893060198 hasAuthorship W1893060198A5012583326 @default.
- W1893060198 hasAuthorship W1893060198A5043882524 @default.
- W1893060198 hasAuthorship W1893060198A5048094864 @default.
- W1893060198 hasAuthorship W1893060198A5064351361 @default.
- W1893060198 hasAuthorship W1893060198A5064574530 @default.
- W1893060198 hasAuthorship W1893060198A5084293838 @default.
- W1893060198 hasConcept C126322002 @default.
- W1893060198 hasConcept C16005928 @default.
- W1893060198 hasConcept C17991360 @default.
- W1893060198 hasConcept C2777011040 @default.
- W1893060198 hasConcept C2780132546 @default.
- W1893060198 hasConcept C2780564577 @default.
- W1893060198 hasConcept C2989005 @default.
- W1893060198 hasConcept C71924100 @default.
- W1893060198 hasConcept C90924648 @default.
- W1893060198 hasConceptScore W1893060198C126322002 @default.
- W1893060198 hasConceptScore W1893060198C16005928 @default.
- W1893060198 hasConceptScore W1893060198C17991360 @default.
- W1893060198 hasConceptScore W1893060198C2777011040 @default.
- W1893060198 hasConceptScore W1893060198C2780132546 @default.
- W1893060198 hasConceptScore W1893060198C2780564577 @default.
- W1893060198 hasConceptScore W1893060198C2989005 @default.
- W1893060198 hasConceptScore W1893060198C71924100 @default.
- W1893060198 hasConceptScore W1893060198C90924648 @default.
- W1893060198 hasIssue "4" @default.
- W1893060198 hasLocation W18930601981 @default.
- W1893060198 hasLocation W18930601982 @default.
- W1893060198 hasOpenAccess W1893060198 @default.
- W1893060198 hasPrimaryLocation W18930601981 @default.
- W1893060198 hasRelatedWork W1986850072 @default.
- W1893060198 hasRelatedWork W2114531367 @default.
- W1893060198 hasRelatedWork W2331246794 @default.
- W1893060198 hasRelatedWork W2588369178 @default.
- W1893060198 hasRelatedWork W2766130161 @default.
- W1893060198 hasRelatedWork W2781166685 @default.
- W1893060198 hasRelatedWork W2803852317 @default.
- W1893060198 hasRelatedWork W3022724713 @default.
- W1893060198 hasRelatedWork W3176363967 @default.
- W1893060198 hasRelatedWork W2343185506 @default.
- W1893060198 hasVolume "27" @default.
- W1893060198 isParatext "false" @default.
- W1893060198 isRetracted "false" @default.
- W1893060198 magId "1893060198" @default.
- W1893060198 workType "article" @default.